Fig. 2

Liver metastases from malignant melanoma which showed early pseudoprogression during treatment with nivolumab. a Liver metastases (arrowhead indicates the target lesion: 31 mm) before the start of treatment with nivolumab. b CT at the 3-month assessment: the liver metastases had increased in size (target lesion: 63 mm). c CT at the 5-month assessment: the liver metastases had shrunk (target lesion: 31 mm), associated with a change of the density. d CT at the 8-month assessment: the target lesion was 20 mm in diameter. e CT at the 12-month assessment: the target lesion was 13 mm in diameter